Market Overview

INVESTIGATION REMINDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm


Schall Law Firm
, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of
Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") (NYSE: AMPE)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.

The investigation focuses on whether the Company issued false and/or
misleading statements and/or failed to disclose information pertinent to
investors. Ampio filed a Form 8-K with the SEC after regular trading
hours ended on August 7, 2018. The purpose of the Form 8-K was to
provide an update on the FDA's review of Ampion, and specifically the
AP-003-A and AP-003-C trials. Ampio informed the market that it met with
the FDA in July, 2018, and received a response letter after that meeting
which stated, "as a single trial[,] the AP-003-A study alone does not
appear to provide sufficient evidence of effectiveness to support [the
Biologics License Application]." The FDA also stated, "the FDA does not
consider the AP-003-C trial to be an adequate and well-controlled
clinical trial." Based on this news, shares of Ampio fell almost 79% on
August 8, 2018.

If you are a shareholder who suffered a loss, click
here to participate

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite
404, Los Angeles, CA 90067
, at 424-303-1964, to discuss your
rights free of charge. You can also reach us through the firm's website
or by email at

The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.

View Comments and Join the Discussion!